Open Access

Memantine for prevention of migraine: a retrospective study of 60 cases

  • Andrew Charles1Email author,
  • Charles Flippen1,
  • Marcela Romero Reyes1 and
  • Kevin C. Brennan1
The Journal of Headache and PainOfficial Journal of the European Headache Federation20078:406

https://doi.org/10.1007/s10194-007-0406-7

Received: 2 May 2007

Accepted: 21 June 2007

Published: 24 September 2007

Abstract

The objective was to retrospectively characterise the efficacy of memantine as preventive therapy in a series of patients with frequent migraine. Patients in a university headache clinic completed a survey regarding their experience with memantine, and medical records were reviewed. All patients who received memantine as preventive therapy for migraine over a 15-month period were mailed surveys and consent forms for record review. Patients were treated with memantine beginning at a dose of 5 mg/day, increasing if needed by 5 mg/week up to 10 mg twice a day. The majority of patients (36 out of 54) treated with memantine for at least 2 months reported a significant reduction in estimated headache frequency, and improved function. Side effects were uncommon and generally mild. This limited retrospective case review suggests that memantine may be an effective preventive therapy for patients with frequent migraine. A prospective trial is warranted.

Keywords

Migraine Headache Prevention Memantine Glutamate